Skip to main content

Table 4 Effect of tolvaptan 60 mg at baseline, during and after systemic inhibition of NO synthesis on plasma concentrations of renin (PRC), angiotensin II (P-AngII) and aldosterone (P-Aldo) in a randomized, placebo-controlled, double-blind, crossover study of 18 ADPKD patients

From: Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study

Periods Prior to L-NMMA infusion period At the end of L-NMMA infusion period 1 h after L-NMMA infusion period P (GLM-within)
PRC(pg/ml)
 Placebo 8.8 ± 5.3 7.4 ± 4.0 7.7 ± 4.3 0.610
 Tolvaptan 60 mg 10.1 ± 5.8 8.9 ± 6.1 8.4 ± 4.9
 p (GLM between) 0.489    
 p (paired t-test, between) 0.481 0.312 0.523  
P-AngII (pg/ml)
 Placebo 7.8 ± 3.8 7.4 ± 3.8 7.1 ± 3.1 0.801
 Tolvaptan 60 mg 9.1 ± 5.9 8.9 ± 4.7 8.6 ± 4.3
 p (GLM between) 0.327    
 p (paired t-test, between) 0.377 0.151 0.261  
P- Aldo (pmol/L)
 Placebo 125 (68; 168) 127 (99; 224) 119 (87; 224)  
 Tolvaptan 60 mg 115 (87; 180) 147 (115; 205) 178 (108; 264)
 p (Wilcoxon’s signed rank test, between) 0.420 0.433 0.170
  1. Data are given as mean ± SD or median with 25th and 75th percentiles in parentheses. General linear model (GLM) with repeated measures was performed for comparison within and between groups. Post-hoc Bonferoni test was used for comparison between L-NMMA infusion period (at the end of L-NMMA infusion period) vs baseline (prior to L-NMMA infusion period) and at baseline vs post infusion period (1 h after L-NMMA infusion period) vs baseline period, none of the p- values were significant. Paired t-test was performed to test differences between treatment groups